RNS Number : 7325U
Genedrive PLC
06 December 2021

genedrive plc
("genedrive" or the "Company")

Additional Listing of Shares

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that 500,000 new Ordinary Shares of 1.5p each in the Company ('New Ordinary Shares') have been issued to the former owner of Visible Genomics Limited as part of a Deed of Amendment agreed in December 2018. This is the final tranche of new ordinary shares to be issued pursuant to the original sale and purchase agreement and the details of this tranche were most recently set out in the Company's audited final results issued on 9 November 2021. The New Ordinary Shares are subject to various restrictions on sale for a period of 24 months.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 10 December 2021. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

Following admission, the Company's issued share capital will comprise 92,270,900 Ordinary Shares with voting rights (' Ordinary Shares'). No Ordinary Shares are held in Treasury. As such, the number of Ordinary Shares with voting rights is 92,270,900. This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel

finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780
or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSUNSNRAAUURAA